<DOC>
	<DOCNO>NCT02489435</DOCNO>
	<brief_summary>The purpose study assess safety tolerability VM-1500 determine main pharmacokinetic parameter VM-1500 multiple oral administration adult healthy subject .</brief_summary>
	<brief_title>Clinical Trial Safety Pharmacokinetics VM-1500 After Multiple Oral Administration Healthy Volunteers</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , phase Ib study healthy volunteer dose escalation identify optimal dose schedule VM-1500 . A total 36 subject treat VM-1500 placebo 14 day follow-up four week . Subjects randomize 3 cohort 3:1 drug/placebo ratio : Cohort 1 ( n=12 ) : 10 mg VM-1500 9 volunteer , Placebo 3 volunteer ; Cohort 2 ( n=12 ) : 20 mg VM-1500 9 volunteer , Placebo 3 volunteer ; Cohort 3 ( n=12 ) : 30 mg VM-1500 9 volunteer , Placebo 3 volunteer ; Decision escalate next ( high ) dose make Independent Safety Review Board ( ISRB ) , establish specifically study . ISRB base decision safety data obtain drug administration cohort analysis clinical lab data obtain within course study . Study time line : - Screening period - 30 day - Treatment period - 14 day dose ( Day 1-14 ) - 2 hospitalization : Day 1-3 , Day 13-15 - 28 PK sample plasma : Day1 - predose , 0,25 ; 0,5 ; 1 ; 1,5 ; 2 ; 3 ; 4 ; 8 ; 12 hour Day 3 , Day 5 , Day 7 , Day 9 , Day 11 , Day 13 - dosing Day 14 ( feed condition ) - dosing , 0,5 ; 1 ; 2 ; 4 ; 8 ; 12h Day 16 , Day 23 , Day 30 , Day 37 , Day 44 PK blood cell - Day 1 ( predose , 4h , 8h ) , Day 3 , 5,7 , 9 , 11 , 13 , 14 - Post treatment follow-up period 30 day .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . Provided sign write informed consent ; 2 . Healthy male subject , 1850 year age ; 3 . Use adequate reliable form contraception study 3 month discontinuation study medication . 4 . ICF sign prior studyrelated procedure . 1 . HIV , hepatitis B , C antibodies plasma ; 2 . Clinical relevant laboratory abnormality ; 3 . Active tobacco , alcohol drug abuse ; 4 . Anticipated noncompliance protocol ; 5 . Patients take investigational drug 3 month prior start study ; 6 . Plasma donorship , surgery 12 week prior start study ; 7 . Current significant gastrointestinal , renal , liver , bronchopulmonary , biliary , neurological , cardiovascular , oncologic , allergic , ophthalmologic disease , include history cataracts/lens opacity .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>